Table 3.
Characteristics | Disease-free survival |
Cause-specific survival |
||
---|---|---|---|---|
Adjusted-HR (95%CI) | P-value | Adjusted-HR (95%CI) | P-value | |
Age (years) | ||||
≥50 | 1 | 1 | ||
<50 | 1.567 (1.125–2.181) | 0.008 | 2.166 (1.454–3.224) | <0.001 |
Histology | ||||
SCC | 1 | 1 | ||
Non-SCC | 2.205 (1.587–3.064) | <0.001 | 2.139 (1.446–3.163) | <0.001 |
Pelvic lymph node | <0.001a | <0.001a | ||
Not involved | 1 | 1 | ||
Single metastasis | 1.234 (0.720–2.113) | 0.445 | 1.013 (0.482–2.128) | 0.974 |
Multiple metastasis | 2.535 (1.726–3.725) | <0.001 | 2.725 (1.686–4.404) | <0.001 |
Missing | - | - | - | - |
Para-aortic lymph node | 0.004a | 0.012a | ||
Not involved | 1 | 1 | ||
Single metastasis | 1.422 (0.654–3.090) | 0.375 | 1.647 (0.690–3.932) | 0.261 |
Multiple metastasis | 2.428 (1.286–4.584) | 0.006 | 2.466 (1.163–5.228) | 0.019 |
Clinically not involved | 0.909 (0.594–1.391) | 0.660 | 0.913 (0.535–1.556) | 0.737 |
Cox proportional hazard regression models for multivariate analysis (conditional backward). Only significant covariates (P < 0.05) in the final models were shown in the table.
P-value for interaction. – suppressed due to number <5. Abbreviations: HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; Adeno, adenocarcinoma; AS, adenosquamous; DSI, deep stromal invasion; LVSI, lympho-vascular space invasion; RT, whole pelvic radiotherapy; CCRT, concurrent chemo-radiotherapy.